The European Medicines Agency (EMA) presented on Tuesday (1 August) a business continuity plan aimed at tackling the potential challenges poised by its relocation from London to another member state after the Brexit decision.
Hosting the European Medicines Agency brings considerable economic benefits to the host city as the service employs more than 1,000 people, paid by the EU. Athens and Milan are keen to secure a slice of this lucrative pie.
Spanish Minister for Health Dolors Montserrat said today (24 May) that Barcelona is “first in the class” in meeting all the criteria to host the European Medicines Agency (EMA). She also insisted that the central government supports Catalonia's bid to host it after Brexit.
Portugal is the latest member state to try and poach the UK-based European Medicines Agency after Brexit. In an interview with EURACTIV.com, Portugal’s junior minister for European affairs insisted having two EU agencies based in Lisbon already would not hurt its chances.
EU officials claim there is growing support for a proposal to close the European Parliament’s expensive second seat in Strasbourg and to sweeten the deal by giving the French city the European Medicine Agency in return.
Public sector jobs in the United Kingdom and in the EU itself are far from safe from the uncertainty generated by Brexit. UK public services are already suffering and British civil servants could be put out to pasture by Brussels.
Europe's drugmakers pushed for a decision as early as June on the new location for the headquarters of the bloc's medicines watchdog, which will relocate from London after Britain's decision to leave the EU.
The criteria regarding the relocation of the European Medicines Agency (EMA) from London after the Brexit vote should not be political, Danish and Greek officials told Euractiv.com on Monday (20 February).
In the aftermath of the Brexit vote, Rome and Madrid are leading the race to gain the right to host influential EU agencies, while Croatia, Bulgaria, Cyprus, Romania and Slovakia could remain empty-handed.
The General Court of the European Union has ordered the European Medicines Agency (EMA) not to release documents on clinical trials, after two access-to-documents were requested, at least until the Court has issued a final ruling.
Jim Murray argues that the European Commission's health and consumers department (DG SANCO) must take the lead in ensuring the European Medicines Agency's (EMA) independence in approving drugs and medicines.